Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as EBV-specific T cells (EBV-CTLs)
EBV-specific T cells · 1 trial · 3 indications
The ORR is defined as percentage of participants with best overall response of complete remission/response (CR) or partial remission/response (PR) based on investigator's assessment. For participants with clinically and/or radiologically evident EBV LPD or malignancies, CR is complete resolution of all clinical and radiologic evidence of lymphoma, confirmed by biopsy of the affected tissues when indicated, lasting for at least 3 weeks following completion of a cycle of tabelecleucel; and PR is a 50 % or greater reduction in the size of all lymphomatous lesions as determined by computed tomography (CT) or magnetic resonance imaging (MRI) measurements of tumor volume, which was maintained for at least 3 weeks following completion of a cycle of tabelecleucel. For participants without clinically and/or radiologically evident tumors with increasing levels of EBV DNA, CR is clearance of EBV without subsequent development of EBV+ LPD; and PR is at least a 10-fold decrease in EBV DNA levels.
| Arm | Type | Description |
|---|---|---|
| HCT EBV+ PTLD R/R Rituximab | EXPERIMENTAL | Patients with Epstein-Barr virus positive (EBV+) posttransplant lymphoproliferative disorders (PTLD) hematopoietic cell transplant (HCT) who were relapse/refractory (R/R) to rituximab will receive IV infusion of tabelecleucel 2 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity. |
| SOT EBV+ PTLD R/R Rituximab | EXPERIMENTAL | Patients with EBV+PTLD solid organ transplant (SOT) who were R/R to rituximab or R/R to rituximab and chemotherapy will receive IV infusion of tabelecleucel 2 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After 3 week observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity. |
| EBV+ AID-LPD | EXPERIMENTAL | Patients with EBV+ acquired immunodeficiency (AID) lymphoproliferative disorder (LPD) will receive IV infusion of tabelecleucel 2 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity |
| EBV+ PID-LPD | EXPERIMENTAL | Patients with EBV+ primary immunodeficiency (PID) LPD will receive IV infusion of tabelecleucel 2 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity. |
| EBV+ Viremia | EXPERIMENTAL | Patients with EBV+ viremia will receive IV infusion of tabelecleucel 2 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity. |
| EBV+ Leiomyosarcoma | EXPERIMENTAL | Patients with EBV+ leiomyosarcoma (LMS) will receive IV infusion of tabelecleucel 2 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity. |
| EBV+ Lymphoma | EXPERIMENTAL | Patients with EBV+ lymphoma will receive IV infusion of tabelecleucel 2 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity. |
| EBV+ NPC | EXPERIMENTAL | Patients with EBV+ nasopharyngeal carcinoma (NPC) will receive IV infusion of tabelecleucel 2 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity. |
| EBV+ Other Solid Tumor | EXPERIMENTAL | Patients with EBV+ other solid tumors will receive IV infusion of tabelecleucel 2 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity. |
| Name | Type | Description |
|---|---|---|
| EBV-specific T cells (EBV-CTLs) | BIOLOGICAL | EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders. |
Inclusion Criteria: * Pathologically documented EBV antigen positive lymphoproliferative disease, lymphoma or other EBV-associated malignancy. OR * Evaluable disease as demonstrated by clinical and/or radiologic studies with current or prior elevated blood levels of EBV DNA exceeding 500 copies/m...
EBV-specific T cells are being studied for the treatment of EBV-induced lymphomas and other EBV-associated malignancies, including in transplant patients with EBV viremia who are at high risk for developing a recurrent EBV lymphoma. The therapy is in Phase 2 clinical development.
EBV-specific T cells are being developed by Atara Biotherapeutics, Inc., which trades on the Nasdaq under the ticker ATRA. The company is the sponsor of the clinical program evaluating this therapy in EBV-associated cancers.
EBV-specific T cells are in Phase 2 clinical development. The program has one completed Phase 2 trial and no active trials. The therapy is investigational and has not been approved by the FDA for any indication.
EBV-specific T cells have been evaluated in one completed Phase 2 trial, NCT01498484, titled Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies. The trial enrolled 87 participants in the United States.
Yes, EBV-specific T cells are also known as EBV-specific T cells (EBV-CTLs). EBV-CTLs stands for Epstein-Barr virus-specific cytotoxic T lymphocytes, which is another name for the same investigational therapy developed by Atara Biotherapeutics.